WO2006041290A3 - Moyens et procedes permettant de contrer un organisme - Google Patents

Moyens et procedes permettant de contrer un organisme Download PDF

Info

Publication number
WO2006041290A3
WO2006041290A3 PCT/NL2005/000739 NL2005000739W WO2006041290A3 WO 2006041290 A3 WO2006041290 A3 WO 2006041290A3 NL 2005000739 W NL2005000739 W NL 2005000739W WO 2006041290 A3 WO2006041290 A3 WO 2006041290A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
organism
acid sequence
sequence
nucleic acids
Prior art date
Application number
PCT/NL2005/000739
Other languages
English (en)
Other versions
WO2006041290A2 (fr
Inventor
Benjamin Berkhout
Brake Olivier Ter
Original Assignee
Amc Amsterdam
Benjamin Berkhout
Brake Olivier Ter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amc Amsterdam, Benjamin Berkhout, Brake Olivier Ter filed Critical Amc Amsterdam
Priority to US11/665,510 priority Critical patent/US20080274991A1/en
Priority to EP05794169A priority patent/EP1799824A2/fr
Publication of WO2006041290A2 publication Critical patent/WO2006041290A2/fr
Publication of WO2006041290A3 publication Critical patent/WO2006041290A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Molécule d'acide nucléique comprenant une séquence complémentaire d'un mutant d'une séquence d'acide nucléique génomique d'un organisme apte à muter son génome. ette séquence d'acide nucléique génomique comprend, d'une part, de préférence une région conservée et essentielle et, d'autre part, une séquence de codage et une séquence de régulation ADN/ARN. Composition pharmaceutique et véhicule d'administration de gènes comprenant une molécule d'acide nucléique de cette invention, ainsi que procédé contrant un organisme consistant à doter cet organisme de la molécule d'acide nucléique. Par ailleurs, cet organisme est doté d'une séquence d'acide nucléique complémentaire avec une séquence d'acide nucléique génomique de cet organisme.
PCT/NL2005/000739 2004-10-15 2005-10-14 Moyens et procedes permettant de contrer un organisme WO2006041290A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/665,510 US20080274991A1 (en) 2004-10-15 2005-10-14 Nucleic Acids Against Viruses, in Particular Hiv
EP05794169A EP1799824A2 (fr) 2004-10-15 2005-10-14 Acides nucleiques contre des virus, en particulier contre le vih

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04077855.7 2004-10-15
EP04077855A EP1647595A1 (fr) 2004-10-15 2004-10-15 Acides nucléiques contre des virus, en particulier contre le VIH

Publications (2)

Publication Number Publication Date
WO2006041290A2 WO2006041290A2 (fr) 2006-04-20
WO2006041290A3 true WO2006041290A3 (fr) 2007-01-18

Family

ID=34928575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2005/000739 WO2006041290A2 (fr) 2004-10-15 2005-10-14 Moyens et procedes permettant de contrer un organisme

Country Status (3)

Country Link
US (1) US20080274991A1 (fr)
EP (2) EP1647595A1 (fr)
WO (1) WO2006041290A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067032A1 (fr) * 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Moyen et methodes permettant d'influencer la stabilite de cellules
DK2540820T3 (en) 2005-12-09 2018-03-12 Academisch Medisch Centrum Bij De Univ Van Amsterdam METHODS AND PROCEDURES FOR AFFECTING THE STABILITY OF ANTIBODY-PRODUCING CELLS
EP2308514B1 (fr) 2007-03-23 2013-06-05 to-BBB Holding B.V. Conjugés pour le transport de médicaments à travers la barrière hémato-encéphalique
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
WO2010098667A1 (fr) * 2009-02-27 2010-09-02 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Moyens et procédés d'inhibition durable des pathogènes
AU2010271583B2 (en) 2009-07-15 2015-02-12 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
PL2646466T3 (pl) 2010-12-02 2017-09-29 Aimm Therapeutics B.V. Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie
WO2014037712A2 (fr) * 2012-09-04 2014-03-13 Genome Research Limited Détection du vih-1
US10611829B2 (en) 2014-01-31 2020-04-07 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
EP3319631A4 (fr) 2015-07-08 2019-01-09 American Gene Technologies International Inc. Pré-immunisation et immunothérapie du vih
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7260898B2 (ja) 2016-01-15 2023-04-19 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド ガンマデルタｔ細胞の活性化のための方法および組成物
WO2017139065A1 (fr) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Vaccination et immunothérapie contre le vih
EP3426777B1 (fr) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Vecteurs de combinaison et méthodes de traitement du cancer
WO2017213697A1 (fr) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Système d'administration viral sans intégration et procédés associés à ce dernier
JP6971492B2 (ja) 2016-07-08 2021-11-24 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
JP2020512815A (ja) 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008146A1 (fr) * 1988-02-26 1989-09-08 Worcester Foundation For Experimental Biology Inhibition du htlv-iii par des oligonucleotides exogenes
US5684147A (en) * 1992-10-05 1997-11-04 Hybridon, Inc. Therapeutic anti-HIV anti-viral oligonucleotides and pharmaceutical formulations thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007367A1 (fr) * 1992-09-29 1994-04-14 Apollon, Inc. Oligomeres antiviraux liant des voies de polypurine d'arn monocatenaire ou d'hybrides d'arn-adn
US6001558A (en) * 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008146A1 (fr) * 1988-02-26 1989-09-08 Worcester Foundation For Experimental Biology Inhibition du htlv-iii par des oligonucleotides exogenes
US5684147A (en) * 1992-10-05 1997-11-04 Hybridon, Inc. Therapeutic anti-HIV anti-viral oligonucleotides and pharmaceutical formulations thereof

Also Published As

Publication number Publication date
US20080274991A1 (en) 2008-11-06
WO2006041290A2 (fr) 2006-04-20
EP1799824A2 (fr) 2007-06-27
EP1647595A1 (fr) 2006-04-19

Similar Documents

Publication Publication Date Title
WO2006041290A3 (fr) Moyens et procedes permettant de contrer un organisme
EP1963525B2 (fr) Synthese de molecules d'acides nucleiques a reduction d'erreurs
EP2270161A3 (fr) Constructions d'expression de promoteur de polymérase III à multiples ARN
WO2007051462A3 (fr) Utilisation de composes tetraorganosilicium
WO2006113246A3 (fr) Molecules arn a faible activation
WO2008051530A3 (fr) Enzymes polymèrases et réactifs pour le séquençage amélioré d'acides nucléiques
WO2010090857A3 (fr) Procédés d'amplification d'acides nucléiques du virus de l'hépatite c
WO2007002008A3 (fr) Procedes et compositions permettant d'exprimer un virus a arn sens negatif dans des cellules canines
WO2006074162A3 (fr) Amplification en cercle roulant pour la production d'amorces
WO2007014275A3 (fr) Integration et expression ciblees de sequences d'acides nucleiques exogenes
WO2005097205A8 (fr) Micro-arn de virus a adn et procedes d'inhibition associes
EP2527445A3 (fr) Traitement et prévention de la grippe
WO2008093847A1 (fr) Adn codant pour la xylitol déshydrogénase
WO2007124327A3 (fr) Méthodes et compositions d'expression d'arn viral sens négatif dans des cellules canines
WO2006136448A3 (fr) Sras attenue: utilisation comme vaccin
WO2007136835A3 (fr) Procédés et cellules pour créer une diversité fonctionnelle et utilisations de ces procédés et de ces cellules
WO2007050990A3 (fr) Amplification d'acides nucleiques au moyen d'amorces non aleatoires
WO2007110628A3 (fr) Construction
WO2009010251A8 (fr) Adn polymérases mutantes et procédés associés
WO2009007934A3 (fr) Variants d'épissage de cd44 dans des maladies neurodégénératives
US11306305B2 (en) Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions
WO2003104470A3 (fr) Retrons pour le ciblage de gène
WO2005066344A3 (fr) Nouveaux plasmides, leurs derives et fragments, leur procedes de fabrication et leur application
WO2022058755A1 (fr) Vecteur d'expression auto-ciblé
WO2007035685A3 (fr) Compositions et procedes de purification d'acides nucleiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005794169

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11665510

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005794169

Country of ref document: EP